Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
DermatologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Oncology
- Publicado em
- 15 abr 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, Victoria Atkinson, Mario Santinami, Dirk Schadendorf, Axel Hauschild, Michael Millward, Mario MandalÁ, Vanna Chiarion-Sileni et al.
Descritores MeSH
- Polymerase Chain Reaction
- Skin Neoplasms
- Biomarkers, Tumor
- Circulating Tumor DNA
- Proto-Oncogene Proteins B-raf
- Melanoma
- Antineoplastic Combined Chemotherapy Protocols
- Humans
- Female
- Aged